Was the implementation strategy of the ProACT trial adequately proactive?

Alexander G Mathioudakis; Jørgen Vestbo

doi:10.1183/20734735.0338-2018

Was the implementation strategy of the ProACT trial adequately proactive?

Breathe (Sheff). 2019 Mar;15(1):77-80. doi: 10.1183/20734735.0338-2018.

Authors

Alexander G Mathioudakis¹, Jørgen Vestbo¹

Affiliation

¹ Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, Manchester, UK.

Abstract

The ProACT trial does not inform the evidence base regarding safety and clinical effectiveness of procalcitonin (PCT) as a biomarker to guide antibiotic administration for LRTIs, but reveals potential challenges in the introduction of PCT in real life. http://ow.ly/Enfr30n2TK6.